/EGTX.ST

EGTX.ST Stock - Egetis Therapeutics AB (publ)

Q: What is the analyst price target for EGTX.ST?

Analyst price target information is not currently available for EGTX.ST.

Q: What is EGTX.ST's market cap?

Market capitalization information is not currently available for EGTX.ST.

Healthcare|Biotechnology|STO

$5.30+0.95%

+$0.05 (+0.95%) • Dec 23

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $5.83

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for EGTX.ST

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta1.26

52W High$7.28

52W Low$3.02

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$46.10M	$57.60M	$22.50M	$38.24M	$40.66M
Gross Profit	$34.50M	$-146,900,000	$-120,100,000	$-58,284,000	$-144,509,000
Gross Margin	74.8%	-255.0%	-533.8%	-152.4%	-355.4%
Operating Income	$-329,400,000	$-324,800,000	$-198,100,000	$-105,681,000	$-178,395,000
Net Income	$-343,600,000	$-326,900,000	$-189,500,000	$-104,730,000	$-179,121,000
Net Margin	-745.3%	-567.5%	-842.2%	-273.9%	-440.5%
EPS	$-1.12	$-1.27	$-0.98	$-0.58	$-2.44

Company Overview

Egetis Therapeutics AB (publ), a pharmaceutical drug development company, focuses on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment. Its products pipeline includes Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning, which is in phase IIb/III clinical trial; and Emcitate, a drug for the treatment of MCT8 deficiency, a rare inborn error of thyroid hormone signaling that is in phase IIb/III clinical trial. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020. Egetis Therapeutics AB (publ) was incorporated in 2006 and is based in Stockholm, Sweden.

Visit Website

Earnings History & Surprises

EGTX.ST

Beat Rate

28%

Last 18 quarters

Avg Surprise

-9.6%

EPS vs Estimate

Beats / Misses

5/11

2 met exactly

Latest EPS

$-0.23

Q4 2025

EPS Surprise History

Q1 24

0.0%

$-0.30vs$-0.30

Q2 24

+3.2%

$-0.30vs$-0.31

Q3 24

+31.0%

$-0.20vs$-0.29

Q4 24

0.0%

$-0.30vs$-0.30

Q1 25

-15.4%

$-0.30vs$-0.26

Q2 25

+16.7%

$-0.20vs$-0.24

Q3 25

-7.9%

$-0.22vs$-0.20

Q4 25

-17.6%

$-0.23vs$-0.20

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2026	Apr 28, 2026	—	—	—	—
Q1 2026	Feb 24, 2026	—	—	—	—
Q4 2025	Nov 25, 2025	$-0.20	$-0.23	-17.6%	✗ MISS
Q3 2025	Aug 21, 2025	$-0.20	$-0.22	-7.9%	✗ MISS
Q2 2025	May 1, 2025	$-0.24	$-0.20	+16.7%	✓ BEAT
Q1 2025	Feb 26, 2025	$-0.26	$-0.30	-15.4%	✗ MISS
Q4 2024	Nov 8, 2024	$-0.30	$-0.30	0.0%	= MET
Q3 2024	Aug 22, 2024	$-0.29	$-0.20	+31.0%	✓ BEAT
Q2 2024	May 3, 2024	$-0.31	$-0.30	+3.2%	✓ BEAT
Q1 2024	Feb 22, 2024	$-0.30	$-0.30	0.0%	= MET
Q4 2023	Nov 8, 2023	$-0.21	$-0.30	-42.9%	✗ MISS
Q3 2023	Aug 22, 2023	$-0.26	$-0.30	-15.4%	✗ MISS
Q2 2023	Apr 26, 2023	$-0.28	$-0.30	-7.1%	✗ MISS
Q1 2023	Feb 22, 2023	$-0.21	$-0.40	-90.5%	✗ MISS
Q4 2022	Nov 8, 2022	$-0.18	$-0.30	-66.7%	✗ MISS
Q3 2022	Aug 19, 2022	$-0.21	$-0.20	+4.8%	✓ BEAT
Q2 2022	Apr 26, 2022	$-0.17	$-0.18	-5.9%	✗ MISS
Q1 2022	Feb 17, 2022	$-0.17	$-0.18	-5.9%	✗ MISS
Q4 2021	Nov 4, 2021	$-0.19	$-0.09	+52.6%	✓ BEAT
Q3 2021	Aug 19, 2021	$-0.17	$-0.18	-5.9%	✗ MISS

Frequently Asked Questions about EGTX.ST

What is EGTX.ST's current stock price?

Egetis Therapeutics AB (publ) (EGTX.ST) is currently trading at $5.30 per share. The stock has moved +0.95% today.

What is the analyst price target for EGTX.ST?

No analyst price targets are currently available for this stock.

What sector is Egetis Therapeutics AB (publ) in?

Egetis Therapeutics AB (publ) operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the STO exchange.

What is EGTX.ST's market cap?

Egetis Therapeutics AB (publ) has a market capitalization of $1.90 billion, making it a small-cap company.

Does EGTX.ST pay dividends?

No, Egetis Therapeutics AB (publ) does not currently pay a dividend to shareholders.